KR100830268B1 - 단백질 합성 억제 유전자의 발현 증강제 - Google Patents

단백질 합성 억제 유전자의 발현 증강제 Download PDF

Info

Publication number
KR100830268B1
KR100830268B1 KR1020027008401A KR20027008401A KR100830268B1 KR 100830268 B1 KR100830268 B1 KR 100830268B1 KR 1020027008401 A KR1020027008401 A KR 1020027008401A KR 20027008401 A KR20027008401 A KR 20027008401A KR 100830268 B1 KR100830268 B1 KR 100830268B1
Authority
KR
South Korea
Prior art keywords
ifn
gene
subtype
expression
protein synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027008401A
Other languages
English (en)
Korean (ko)
Other versions
KR20020065620A (ko
Inventor
야나이요시아키
사노오사무
구리모토마사시
Original Assignee
가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 filed Critical 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조
Publication of KR20020065620A publication Critical patent/KR20020065620A/ko
Application granted granted Critical
Publication of KR100830268B1 publication Critical patent/KR100830268B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
KR1020027008401A 2000-10-27 2001-09-26 단백질 합성 억제 유전자의 발현 증강제 Expired - Fee Related KR100830268B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000328539 2000-10-27
JPJP-P-2000-00328539 2000-10-27
JP2001116710A JP2002201141A (ja) 2000-10-27 2001-04-16 蛋白質合成抑制遺伝子の発現増強剤
JPJP-P-2001-00116710 2001-04-16

Publications (2)

Publication Number Publication Date
KR20020065620A KR20020065620A (ko) 2002-08-13
KR100830268B1 true KR100830268B1 (ko) 2008-05-16

Family

ID=26602905

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027008401A Expired - Fee Related KR100830268B1 (ko) 2000-10-27 2001-09-26 단백질 합성 억제 유전자의 발현 증강제

Country Status (7)

Country Link
US (2) US6773701B2 (cg-RX-API-DMAC7.html)
EP (1) EP1329223A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002201141A (cg-RX-API-DMAC7.html)
KR (1) KR100830268B1 (cg-RX-API-DMAC7.html)
CA (1) CA2395324A1 (cg-RX-API-DMAC7.html)
TW (1) TWI283582B (cg-RX-API-DMAC7.html)
WO (1) WO2002036153A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP4629964B2 (ja) * 2003-09-12 2011-02-09 株式会社林原生物化学研究所 ウシの消化器疾患治療剤
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
EP1867340A4 (en) 2005-03-10 2009-12-23 Hayashibara Biochem Lab THERAPEUTIC AGENT FOR TREATING DISEASES IN THE BOVINE DIGESTIVE SYSTEM
JPWO2007037098A1 (ja) * 2005-09-27 2009-04-02 株式会社林原生物化学研究所 繁殖障害改善剤
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN104056254A (zh) * 2013-03-18 2014-09-24 赛德医药科技股份有限公司 用以降低肝炎病患复发率的组合物
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016107A1 (en) 1992-02-10 1993-08-19 Interferon Sciences, Inc. Improved alpha interferon composition and method for its production from human peripheral blood leukocytes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5142199B2 (cg-RX-API-DMAC7.html) 1972-09-04 1976-11-13
GB2016015B (en) 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
JPS5639022A (en) 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
JPS5654158A (en) 1979-10-09 1981-05-14 Hitachi Ltd Control system for call waiting
JP2838800B2 (ja) 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
JP3232488B2 (ja) 1992-08-20 2001-11-26 株式会社林原生物化学研究所 プルラン高含有物とその製造方法並びに用途
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
JPH07163368A (ja) 1993-12-15 1995-06-27 Hayashibara Biochem Lab Inc 組換えdnaとその組換えdnaを含む形質転換体
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
JP3467515B2 (ja) * 1994-11-01 2003-11-17 財団法人ルイ・パストゥール医学研究センター インターフェロン活性の測定法
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016107A1 (en) 1992-02-10 1993-08-19 Interferon Sciences, Inc. Improved alpha interferon composition and method for its production from human peripheral blood leukocytes

Also Published As

Publication number Publication date
EP1329223A1 (en) 2003-07-23
US6773701B2 (en) 2004-08-10
US20040197307A1 (en) 2004-10-07
US7189389B2 (en) 2007-03-13
CA2395324A1 (en) 2002-05-10
KR20020065620A (ko) 2002-08-13
EP1329223A4 (en) 2005-04-20
JP2002201141A (ja) 2002-07-16
US20030039629A1 (en) 2003-02-27
TWI283582B (en) 2007-07-11
WO2002036153A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
KR100223255B1 (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법
US6060450A (en) Method for treatment of autoimmune diseases
TW542722B (en) Orally-administered interferon-tau compositions
Wang et al. Cynoglossus semilaevis ISG15: a secreted cytokine-like protein that stimulates antiviral immune response in a LRGG motif-dependent manner
KR100496460B1 (ko) 폴리펩티드
US7655628B2 (en) Method for treating liver cirrhosis or interstitial pulmonary fibrosis
CN103483443A (zh) 重组人干扰素样蛋白
Masci et al. New and modified interferon alfas: preclinical and clinical data
US6773701B2 (en) Expression enhancer for protein synthesis inhibitory genes
Taylor Interferons
JP2003327542A (ja) インターフェロン−γの産生を誘導するポリペプチド
EP1326628B1 (en) Chemokine mutants in the treatment of multiple sclerosis
Ooi et al. Biological characterisation of a recombinant Atlantic salmon type I interferon synthesized in Escherichia coli
AU2002215919A1 (en) Chemokine mutants in the treatment of multiple sclerosis
CZ20024094A3 (cs) Farmaceutický přípravek pro léčení sclerosis multiplex obsahující nový interferon
Kim et al. Species specific antiviral activity of porcine interferon-α8 (IFNα8)
Schein et al. Deletions at the C-terminus of interferon γ reduce RNA binding and activation of double-stranded-RNA cleavage by bovine seminal ribonuclease
KASHIMA et al. Expression of bovine cytokines in Escherichia coli
Broeze et al. Studies with Pure Mouse Ehrlich Ascites Tumor Interferons α and β: Patterns of Induction of (2′-5′)(A) n Synthetase and of a Double-Stranded RNA-Dependent Protein Kinase in Mouse Cells and Human Cells
Aboagye‐Mathiesen et al. Interferon gamma regulates a unique set of proteins in fresh human bladder transitional cell carcinomas
Watanabe et al. Interleukin-22 induces immune-related gene expression in the gills of Japanese medaka Oryzias latipes
Hayes Differences between human α (leukocyte) and β (fibroblast) interferons
CN111825773B (zh) 重组人TSG6-IFNα融合蛋白及其制备方法以及其作为抗病毒药物的应用
Kang et al. Amino acid differences in interferon-tau (IFN-τ) of Bos taurus Coreanae and Holstein
RU2003334C1 (ru) Способ лечени больных с опухол ми

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20110428

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120510

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120510